The City of Philadelphia has taken aim at some of the nation's biggest pharmacy benefit managers (PBMs), including heavyweights CVS Caremark, Express Scripts, and Optum, with a lawsuit alleging that their actions have exacerbated the city's opioid crisis, according to a recent statement. The city accuses these companies of deceptive marketing and over-distributing opioids, running afoul of both Philadelphia's Consumer Protection Ordinance and federal and state-controlled substance laws.
Collectively, the accused PBMs manage prescription drug benefits for more than 200 million Americans and process billions of claims each year; they are vilified for their alleged two-decade campaign to boost opioid prescriptions in collaboration with drug manufacturers, highlighting medications like OxyContin on drug lists for profit, at the expense of public health and safety, the city accuses through partnership with co-counsel including well-known law firms such as Dilworth Paxson and Baron & Budd. These PBMs allegedly prioritized their financial gain while downplaying the risks associated with opioid medications, despite having the means to implement safeguarding protocols to combat overprescription.
Mayor Cherelle L. Parker took a strong stance against the PBMs, stating, "Even while knowing the dangers of opioid overuse, these companies chose profit over people," her words reflecting a deep disappointment in the actions these intermediaries between manufacturers, insurers, and pharmacies have taken. The lawsuit seeks compensatory and punitive damages and aims for an injunctive order to force these companies to undertake corrective actions – a remedy for a city that has witnessed firsthand the devastating impact of opioid addiction.
Renee Garcia, City Solicitor, outlined the city's position with conviction, noting that these companies watched as the opioid epidemic ravaged Philadelphia communities and recklessly continued to fuel widespread addiction. They systematically rejected safeguards and put lives at risk while falsely professing a commitment to safety, Garcia contends; these companies continued to actively encourage the liberal prescription of these addictive painkillers despite the clear signs of mounting public health crises, the lawsuit contends. Adam Geer, Chief Public Safety Director, underscored that while direct interventions have reduced fatal overdoses and public safety measures have seen a decline in crime, the contribution of those who benefited and exacerbated the opioid issue is critical for the city to not only persist in recovery but to discharge the responsibility for the havoc wrought across neighborhoods like Kensington.
As the case unfolds, Philadelphia takes a determined stance to not only seek justice for the victims of the opioid crisis but also to hold those in the middle of the pharmaceutical supply chain responsible for their part in the epidemic. The legal battle reflects a broader quest for accountability as communities struggle to heal from the opioid scourge that continues to plague not just the city but also the nation.
